Document Detail

Effects of a novel cardioselective ATP-sensitive potassium channel antagonist, 1-[[5-[2-(5-chloro-o-anisamido)ethyl]-beta-methoxyethoxyphenyl]sulfonyl]-3-methylthiourea, sodium salt (HMR 1402), on susceptibility to ventricular fibrillation induced by myocardial ischemia: in vitro and in vivo studies.
MedLine Citation:
PMID:  14722326     Owner:  NLM     Status:  MEDLINE    
In the present study, a novel sulfonylthiourea, 1-[[5-[2-(5-chloro-o-anisamido)ethyl]-beta-methoxyethoxyphenyl]sulfonyl]-3-methylthiourea, sodium salt (HMR 1402), was investigated using in vitro and in vivo systems. HMR 1402 inhibited rilmakalim-induced currents in rat and guinea pig myocytes (IC(50) = 60 and 509 nM, respectively). Hypoxia-induced shortening of action potential duration at 90% repolarization was also significantly attenuated by HMR 1402 (68.1 +/- 3.9% of control at 0.3 microM). In contrast, HMR 1402 had a smaller effect on pancreatic beta-cells (rat insuloma cells, RINm5F) hyperpolarized with 100 microM diazoxide (IC(50) = 3.9 microM, compared with glibenclamide IC(50) = 9 nM). In a similar manner, hypoxia induced increases in coronary flow in isolated guinea pig hearts were only slightly reduced by HMR 1402. These data strongly suggest that HMR 1402 has pharmacological selectivity for cardiac myocytes and, therefore, may protect against ischemically induced ventricular fibrillation (VF) without the untoward effects of nonselective compounds. To test this hypothesis, VF was induced in 8 dogs with healed myocardial infarctions by a 2-min coronary occlusion during the last minute of exercise. On a subsequent day, the exercise plus ischemia test was repeated after HMR 1402 (3.0 mg/kg i.v., n = 4, infusion 4 microg/kg/min for 1 h before exercise, n = 4). This drug significantly reduced the incidence of VF protecting seven of eight animals (p = 0.0007) without altering plasma insulin, blood glucose, or the increases in mean coronary blood flow induced by either exercise or 15-s coronary occlusions. Thus, the ATP-sensitive potassium channel antagonist HMR 1402 can prevent ischemically induced VF without altering coronary blood flow or blood glucose.
George E Billman; Melanie S Houle; Heinrich C Englert; Heinz Gögelein
Related Documents :
2799866 - Reduction of hyperthermic ischemic acidosis by a conditioning event in cats.
17805086 - Exercise-induced cardioprotection: endogenous mechanisms.
15252386 - Surgical applications of organ preconditioning.
11271276 - Difference in energy metabolism between fresh and warm ischemic canine pancreases durin...
7915026 - A clinical trial of bethanechol in patients with xerostomia after radiation therapy. a ...
23478556 - Cardiovascular considerations in middle-aged athletes at risk for coronary artery disease.
Publication Detail:
Type:  Journal Article     Date:  2004-01-13
Journal Detail:
Title:  The Journal of pharmacology and experimental therapeutics     Volume:  309     ISSN:  0022-3565     ISO Abbreviation:  J. Pharmacol. Exp. Ther.     Publication Date:  2004 Apr 
Date Detail:
Created Date:  2004-03-29     Completed Date:  2004-05-04     Revised Date:  2005-11-17    
Medline Journal Info:
Nlm Unique ID:  0376362     Medline TA:  J Pharmacol Exp Ther     Country:  United States    
Other Details:
Languages:  eng     Pagination:  182-92     Citation Subset:  IM    
Department of Physiology and Cell Biology, The Ohio State University, 304 Hamilton Hall, 1645 Neil Avenue, Columbus, OH 43210-1218, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
ATP-Binding Cassette Transporters
Guinea Pigs
Heart / drug effects*
Hyperemia / prevention & control
Islets of Langerhans / drug effects
Myocardial Ischemia / complications*
Papillary Muscles / drug effects*,  physiology
Patch-Clamp Techniques
Potassium Channel Blockers / pharmacology*,  therapeutic use
Potassium Channels / metabolism*
Potassium Channels, Inwardly Rectifying
Rats, Sprague-Dawley
Thiourea / analogs & derivatives,  pharmacology*
Ventricular Fibrillation / etiology,  prevention & control*
Reg. No./Substance:
0/1-((5-(2-(5-chloro-o-anisamido)ethyl)-beta-methoxyethoxyphenyl)sulfonyl)-3-methylthiourea, sodium salt; 0/ATP-Binding Cassette Transporters; 0/Potassium Channel Blockers; 0/Potassium Channels; 0/Potassium Channels, Inwardly Rectifying; 0/uK-ATP-1 potassium channel; 62-56-6/Thiourea

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Estrogen and progesterone prevent disruption of prepulse inhibition by the serotonin-1A receptor ago...
Next Document:  Paroxetine inhibits acute effects of 3,4-methylenedioxymethamphetamine on the immune system in human...